SCHEMBL29549032

SCHEMBL29549032

COc1ccc(C(C(=O)[C@@H](N)CCCNC(=N)N)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 9/20 0.50
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
CASR P41180 2/20 0.39
KCNH2 Q12809 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
ITGB3 P05106 2/20 0.38
ITGA2B P08514 2/20 0.38
PLAAT3 P53816 1/20 0.38
PLAAT5 Q96KN8 1/20 0.38
PLAAT2 Q9NWW9 1/20 0.38
PLAAT4 Q9UL19 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29549080 1.00 KIF11 (0.50) KIF11NPC1RAB9ACNR1CNR2
SCHEMBL31034866 1.00 KIF11 (0.50) KIF11NPC1RAB9ACNR1CNR2
SCHEMBL29538792 0.89 KIF11 (0.40) KIF11CNR1CNR2
SCHEMBL29864858 0.82 KIF11 (0.55) KIF11KCNH2
SCHEMBL29548987 0.82 CTSK (0.43) KIF11ITGB3ITGA2BHDAC1HDAC7
SCHEMBL30241772 0.81 KIF11 (0.59) KIF11NPC1RAB9ACNR1CNR2
SCHEMBL30241793 0.81 KIF11 (0.59) KIF11NPC1RAB9ACNR1CNR2
SCHEMBL30241754 0.81 KIF11 (0.59) KIF11NPC1RAB9ACNR1CNR2
SCHEMBL29964865 0.81 KIF11 (0.46) KIF11NPC1RAB9ACNR1CNR2
Arginine SCHEMBL29740227 0.78 CA1 (0.48) KIF11NPC1RAB9ACASRITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4525840-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND HTT PROTEINOPATHIES Stealth BioTherapeutics Inc. (US) 2025-03-26 EP disclosed
CN-118725014-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-10-01 CN disclosed
CN-118702766-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-09-27 CN disclosed
CN-118702767-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-09-27 CN disclosed
CN-111954539-B Mitochondrial targeting peptides 隐形生物治疗公司 2024-06-21 CN disclosed
US-20240092832-A1 DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA STEALTH BIOTHERAPEUTICS INC. 2024-03-21 US disclosed
US-20240059734-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2024-02-22 US disclosed
WO-2023224989-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND HTT PROTEINOPATHIES STEALTH BIOTHERAPEUTICS INC. (US) 2023-11-23 WO disclosed
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 US disclosed
EP-4218785-A2 MITOCHONDRIA-TARGETING PEPTIDES Stealth BioTherapeutics Inc. (US) 2023-08-02 EP disclosed
US-20230227499-A1 PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-07-20 US disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 US disclosed
EP-4168424-A1 PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES Stealth BioTherapeutics Inc. (US) 2023-04-26 EP disclosed
EP-3723783-B1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC (US) 2023-02-15 EP disclosed
EP-3986401-A1 THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-I-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Stealth BioTherapeutics Inc. (US) 2022-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227499-A1 PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES PITRM1, NME4, PDF KIF11 3101/4885NPC1 1399/4885RAB9A 2023/4885
US-20240092832-A1 DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA ABAT, SSBP1, PDF KIF11 2163/4885NPC1 3558/4885RAB9A 3706/4885
US-11795196-B2 Mitochondria-targeting peptides HSPE1, TFAM, TNNI3 KIF11 3536/4885NPC1 2673/4885RAB9A 1631/4885
US-20240059734-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 KIF11 3536/4885NPC1 2673/4885RAB9A 1631/4885
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 KIF11 3536/4885NPC1 2673/4885RAB9A 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.